Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model-Reference-Cited by-同舟云学术

Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model

Published:2023-01 Issue: Volume:80 Page:129108
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Vandeveer George H.,Arduini Robert M.,Baker Darren P.,Barry Kevin,Bohnert Tonika,Bowden-Verhoek Jon K.,Conlon Patrick,Cullen Patrick F.,Guan Bing,Jenkins Tracy J.,Liao Shu-Yu,Lin Lin,Liu Yu-Ting,Marcotte Douglas,Mertsching Elisabeth,Metrick Claire M.,Negrou Ella,Powell Noel,Scott Daniel,Silvian Laura F.,Hopkins Brian T.

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference29 articles.

1. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity;Middendorp;J Immunol,2003

2. Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances;Wen;Leukemia,2021

3. Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study);Cohen;Arthritis Rheumatol,2020

4. Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial;Metz;Nat Med,2021

5. Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy;Garcia-Merino;Cells,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrrole-containing hybrids as potential anticancer agents: An insight into current developments and structure-activity relationships;European Journal of Medicinal Chemistry;2024-07